The primary purpose of this study is to compare the PK parameters of a single dose of a test tablet formulation of AKB-6548 relative to a single dose of the reference AKB-6548 tablet formulation, both treatments administered without food, and to compare the PK parameters of the test tablet formulation given under fed and fasted conditions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
18
Unnamed facility
Kalamazoo, Michigan, United States
Bioavailability endpoints: Area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUC 0-t) of AKB-6548
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
Bioavailability endpoints: Area under the concentration time curve from time 0 to infinity (AUC 0-inf) of AKB-6548
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
Bioavailability endpoints: Maximum observed plasma concentration (Cmax) of AKB-6548
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
Food Effect Endpoint: AKB-6548 AUC 0-t for the fed versus fasted administration of AKB-6548 tablets
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
Food Effect Endpoint: AKB-6548 AUC 0-inf for the fed versus fasted administration of AKB-6548 tablets
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
Food Effect Endpoint: AKB-6548 Cmax for the fed versus fasted administration of AKB-6548 tablets
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
PK Parameters of AKB-6548: Maximum observed plasma concentration (Cmax)
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
PK Parameters of AKB-6548: Time to reach Cmax (Tmax)
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
PK Parameters of AKB-6548: Terminal elimination rate constant (λz)
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
PK Parameters of AKB-6548: Terminal elimination half-life (t1/2)
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
PK Parameters of AKB-6548: Area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUC 0-t)
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
PK Parameters of AKB-6548: AUC from time 0 to infinity (AUC 0-inf)
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
AKB-6548: Apparent oral clearance (CL/F)
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose
AKB-6548: Apparent volume of distribution during the terminal phase (Vz/F)
Time frame: Multiple timepoint evaluations from pre-dose to 24 hours post-dose